General
Preferred name
inosine
Synonyms
Groprinosin ()
Isoprinosine ()
Immunovir ()
Delimmun ()
Inosine pranobex ()
Imunovir ()
NSC 20262, INO 495 ()
inosine pranobex, Immunovir, Groprinosin, Delimmun ()
NPT-10381 ()
Viruxan ()
NP-113 ()
Inosine acedobene dimepranol ()
Isoprinosin ()
Aviral ()
Pranosine ()
Pranosina ()
Isoviral ()
Methisoprinol ()
Isoprinosina ()
Imunoviral ()
Inosiplex ()
Modimmunal ()
Inosina ()
NSC-20262 ()
Hypoxanthine riboside ()
INO-1001 ()
Hypoxanthosine ()
Inotin ()
P&D ID
PD008719
CAS
36703-88-5
12712-98-0
58-63-9
Tags
available
drug
drug candidate
Approved by
FDA
Drug Status
approved
investigational
Max Phase
3.0
Drug indication
viral disease
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Inosine pranobex is an orally active immunomodulator. Inosine pranobex has broad-spectrum antiviral activity. Inosine pranobex inhibits human immunodeficiency virus (HIV), herpes simplex virus (HSV), vaccinia virus (VACV), human tumor virus (HPV), Cytomegalovirus, influenza virus (INFV), parainfluenza virus (PIV), and Epstein-Barr virus
TOXICITY
Mouse LD50 (Intravenous ): 1570 mg/kg; Muse LD50 (Oral) : 9410mg/kg; Mouse LD50 (subcutaneous) ; 2960mg/kg
DESCRIPTION
Inosine pranobex (Delimmun) has a number of immunomodulatory effects, including inducing T-lymphocyte differentiation, augmenting macrophage and NK cell functions, and stimulating IL-2 production. Through these effects and others, isoprinosine shows antiviral activity and has applications against subacute sclerosing panencephalitis. It also restores depressed immune responses in Y patients after irradiation and reduces the incidence of infection in leukemia patients undergoing chemotherapy. It is most commonly used to treat the rare measles complication subacute sclerosing panencephalitis in conjunction with intrathecal interferon therapy.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Inosine is a nutritional supplement touted to improve athletic performance. It has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A1 and A2A receptors.
(Enamine Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
0
Compound Sets
22
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugCentral
DrugCentral Approved Drugs
Enamine Bioactive Compounds
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NPC Screening Collection
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
123
Molecular Weight
268.08
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
4
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
2
cLogP
-2.27
TPSA
133.49
Fraction CSP3
0.5
Chiral centers
4.0
Largest ring
6.0
QED
0.48
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
HIV
IL-2
PARP1, PNP
Antiviral,Immunology & Inflammation related
HPV
HSV
Interleukin Related
MOA
neurotrophic agent
Pathway
Anti-infection
Immunology/Inflammation
Microbiology/virology
Proteases/Proteasome
Source data

